SIFI and Polpharma announce cross-licensing deal in ophthalmology
(WorldNews Italy)

This partnership allows both companies to strengthen their ophthalmic product portfolio in Europe. Madrid, Oct. 15, 2018 - SIFI, Italian leader in the development and marketing of ophthalmic therapies, and Polpharma, the leader in the Polish pharmaceutical market, announce a commercial strategic partnership, mainly across Europe. The agreement will permit to enhance product portfolios and provide a more comprehensive therapeutic range of ophthalmic therapies to the international market. Mutually identified areas of collaboration were established and will accelerate growth in the key therapeutic areas of Glaucoma and Dry Eye. Glaucoma is the second leading cause of...